Literature DB >> 26788278

The Effectiveness of Bevacizumab in Radionecrosis After Radiosurgery of a Single Brain Metastasis.

Durim Delishaj1, Stefano Ursino1, Francesco Pasqualetti1, Ilaria Pesaresi2, Ilaria Desideri2, Mirco Cosottini2, Concetta Laliscia1, Fabiola Paiar1, Maria Grazia Fabrini1.   

Abstract

Radionecrosis (RN) of brain tissue is a serious late complication of brain irradiation and historically has been treated with corticos-teroid therapy and alternatively surgical decompression. Recently, bevacizumab has been suggested for treatment of cerebral radiation necrosis. We present a case of a 73-years-old women affected by a primary non-small cell lung cancer with a single brain metastasis treated with radiosurgery. Two years after radiosurgery the patient referred neurological symptoms and a brain magnetic resonance confirmed the presence of RN. The patient refused surgical decompression so underwent at the treatment with bevacizumab 7.5 mg/kg/2 weeks for a total of 4 cycles. After two months of treatment the patient reported strumental and clinical improvement. Ten months after bevacizumab discontinuation the patient experienced a recurrence of RN with evident clinical manifestation and confirmed by radiological imaging. A new treatment with bevacizumab was not performed due to the systemic progression disease and the worsening of clinical status. Despite limited to only one clinical case, our study suggests the efficacy of bevacizumab to treat RN. Future studies are needed to confirm its mechanism and to properly define the optimal scheduling, dosage and duration of therapy.

Entities:  

Keywords:  Bevacizumab; radionecrosis; stereotactic radiotherapy

Year:  2015        PMID: 26788278      PMCID: PMC4703924          DOI: 10.4081/rt.2015.6018

Source DB:  PubMed          Journal:  Rare Tumors        ISSN: 2036-3605


  20 in total

1.  Treatment of steroid refractory, Gamma Knife related radiation necrosis with bevacizumab: case report and review of the literature.

Authors:  Matthew R Sanborn; Shabbar F Danish; Myrna R Rosenfeld; Donald O'Rourke; John Y K Lee
Journal:  Clin Neurol Neurosurg       Date:  2011-09-08       Impact factor: 1.876

2.  Hypoxia in radiation-induced blood-spinal cord barrier breakdown.

Authors:  Y Q Li; J R Ballinger; R A Nordal; Z F Su; C S Wong
Journal:  Cancer Res       Date:  2001-04-15       Impact factor: 12.701

3.  Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system.

Authors:  Victor A Levin; Luc Bidaut; Ping Hou; Ashok J Kumar; Jeffrey S Wefel; B Nebiyou Bekele; Jai Grewal; Sujit Prabhu; Monica Loghin; Mark R Gilbert; Edward F Jackson
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-04-01       Impact factor: 7.038

4.  The distribution of vascular endothelial growth factor-producing cells in clinical radiation necrosis of the brain: pathological consideration of their potential roles.

Authors:  Naosuke Nonoguchi; Shin-Ichi Miyatake; Motoi Fukumoto; Motomasa Furuse; Ryo Hiramatsu; Shinji Kawabata; Toshihiko Kuroiwa; Motomu Tsuji; Manabu Fukumoto; Koji Ono
Journal:  J Neurooncol       Date:  2011-06-18       Impact factor: 4.130

Review 5.  Bevacizumab as a treatment option for radiation-induced cerebral necrosis.

Authors:  Christiane Matuschek; Edwin Bölke; Jens Nawatny; Thomas K Hoffmann; Matthias Peiper; Klaus Orth; Peter Arne Gerber; Ethelyn Rusnak; Guido Lammering; Wilfried Budach
Journal:  Strahlenther Onkol       Date:  2011-01-24       Impact factor: 3.621

6.  Repeated treatments with bevacizumab for recurrent radiation necrosis in patients with malignant brain tumors: a report of 2 cases.

Authors:  Motomasa Furuse; Shinji Kawabata; Toshihiko Kuroiwa; Shin-Ichi Miyatake
Journal:  J Neurooncol       Date:  2010-08-07       Impact factor: 4.130

7.  Bevacizumab treatment in malignant meningioma with additional radiation necrosis. An MRI diffusion and perfusion case study.

Authors:  J P Boström; M Seifert; S Greschus; N Schäfer; M Glas; G Lammering; U Herrlinger
Journal:  Strahlenther Onkol       Date:  2014-01-17       Impact factor: 3.621

8.  Results of contemporary surgical management of radiation necrosis using frameless stereotaxis and intraoperative magnetic resonance imaging.

Authors:  Christopher M McPherson; Ronald E Warnick
Journal:  J Neurooncol       Date:  2004-05       Impact factor: 4.130

9.  Cerebral radiation necrosis: incidence, outcomes, and risk factors with emphasis on radiation parameters and chemotherapy.

Authors:  Jeremy D Ruben; Michael Dally; Michael Bailey; Robin Smith; Catriona A McLean; Pasqual Fedele
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-03-06       Impact factor: 7.038

10.  Bevacizumab as a treatment for radiation necrosis of brain metastases post stereotactic radiosurgery.

Authors:  Dustin Boothe; Robert Young; Yoshiya Yamada; Alisa Prager; Timothy Chan; Kathryn Beal
Journal:  Neuro Oncol       Date:  2013-06-27       Impact factor: 12.300

View more
  4 in total

Review 1.  Brain metastases: neuroimaging.

Authors:  Whitney B Pope
Journal:  Handb Clin Neurol       Date:  2018

Review 2.  Bevacizumab for the Treatment of Radiation-Induced Cerebral Necrosis: A Systematic Review of the Literature.

Authors:  Durim Delishaj; Stefano Ursino; Francesco Pasqualetti; Agostino Cristaudo; Mirco Cosottini; Maria Grazia Fabrini; Fabiola Paiar
Journal:  J Clin Med Res       Date:  2017-02-21

3.  Ultra-Low-Dose Bevacizumab For Cerebral Radiation Necrosis: A Prospective Phase II Clinical Study.

Authors:  Hongqing Zhuang; Hongxia Zhuang; Siyu Shi; Yuxia Wang
Journal:  Onco Targets Ther       Date:  2019-10-11       Impact factor: 4.147

4.  Bevacizumab for pediatric radiation necrosis.

Authors:  Lorena V Baroni; Daniel Alderete; Palma Solano-Paez; Carlos Rugilo; Candela Freytes; Suzanne Laughlin; Adriana Fonseca; Ute Bartels; Uri Tabori; Eric Bouffet; Annie Huang; Normand Laperriere; Derek S Tsang; David Sumerauer; Martin Kyncl; Barbora Ondrová; Vajiranee S Malalasekera; Jordan R Hansford; Michal Zápotocký; Vijay Ramaswamy
Journal:  Neurooncol Pract       Date:  2020-01-20
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.